26.04.24 | Vollzeit | Planegg | Formycon AGOf biosimilar drug development, from market analysis and target definition by protein analytics, to the development of production processes, to clinical trials and the regulatory approval process. Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Formycon
Später ansehen26.04.24 | Vollzeit | Planegg | Formycon AGOf biosimilar drug development, from market analysis and target definition by protein analytics, to the development of production processes, to clinical trials and the regulatory approval process. Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Formycon
Später ansehen26.04.24 | Vollzeit | Planegg | Formycon AGOf biosimilar drug development, from market analysis and target definition by protein analytics, to the development of production processes, to clinical trials and the regulatory approval process. Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Formycon
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHIs markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses and produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHIs markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses and produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHIs markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses and produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHIs markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses and produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHIs markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses and produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical
Später ansehen08.04.24 | Vollzeit | Planegg | CatalYm GmbHIs markedly overexpressed across various tumor types. This novel approach has demonstrated the ability to reinvigorate anti-tumor immune responses and produce clinically significant outcomes in patients previously unresponsive to immunotherapy. Building upon highly promising results from Phase 2 clinical
Später ansehenVerpassen Sie nie wieder einen passenden Job!
Alle Jobs für Clinical in Planegg kostenlos abonnieren.